BioMarin Pharmaceutical (BMRN) said Monday that new clinical data showed its Voxzogo drug had a "meaningful impact" on tibial bowing in children under five years old with achondroplasia.
New studies showed that the drug had a significant reduction in the magnitude of tibial bowing compared to children who received a placebo, and the improvement was sustained in children who received the treatment for several years, the company said in a statement.
Voxzogo also showed early investigational efficacy in other skeletal conditions, according to the company.
BioMarin said it continues to advance its clinical program for Voxzogo in hypochondroplasia, idiopathic short stature, Noonan syndrome, Turner syndrome, and SHOX deficiency.
The company recently completed enrollment in its phase 3 trial for hypochondroplasia and said it expects to report topline data in 2026, with a potential launch targeted for 2027.
Shares of BioMarin were up 4.4% in recent trading.
Price: 61.46, Change: +2.60, Percent Change: +4.42
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。